SCI
15Jan
Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial
RicheldiLuca,FernándezPérezEvansR,CostabelUlrichetal.Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial.[J].LancetRespirMed,,8:25-33.
Background背景
Connectivetissuegrowthfactor(CTGF)isasecretedglycoproteinthathasacentralroleintheprocessoffibrosis.Thisstudywasdesignedtoassessthesafety,tolerability,andefficacyofpamrevlumab(FG-),afullyre